Literature DB >> 32636019

Influence of Influenza Infection on In-Hospital Acute Myocardial Infarction Outcomes.

Byomesh Tripathi1, Varun Kumar2, Ankur Kalra3, Tanush Gupta4, Abhishek C Sawant1, Purnima Sharma1, Shilpkumar Arora5, Muhammad S Panhwar6, Radha Gopalan1, Abhishek Deshmukh7, Ashish Pershad1, Martha Gulati1, Deepak L Bhatt8.   

Abstract

Influenza is associated with significant morbidity in the United States but its influence on in-hospital outcomes in patients with AMI has not been well studied. The Nationwide Readmission Database (NRD) from 2010 to 2014 was queried using the International Classification of Diseases-Ninth edition, Clinical Modification (ICD-9-CM) codes to identify all patients ≥18 years who were admitted for AMI with and without concurrent influenza. Propensity score matching was used to adjust patients' baseline characteristics and co-morbidities. In-hospital mortality, 30-day readmission rates, in-hospital complications, and resource utilization were analyzed. We identified a total of 2,428,361 patients admitted with AMI, of whom 3,006 (0.12%) had coexisting influenza. We noted significantly higher in-hospital mortality (7.7% vs 5.6%, p <0.01) and 30-day readmission rates (15.8% vs 14.1%, p <0.01) in patients with influenza compared with those without it. After propensity matching, the differences in in-hospital mortality and 30-day readmission were no longer statistically significant between the groups. Patients with influenza had a higher incidence of acute kidney injury (30.9% vs 24.6%, p <0.01), acute respiratory failure (50.2% vs 32.2%, p <0.01), need for mechanical ventilation (13.9% vs 9.2%, p <0.01), and sepsis (10% vs 3.8%, p <0.01) in the matched cohort. Patients with influenza had longer hospital stays (8.4 days vs 6.4 days, p <0.01) and mean costs of care (26,200USD vs 23,400USD, p <0.01). In conclusion, AMI patients with concomitant influenza infection had higher in-hospital mortality, 30-day readmission, in-hospital complications, and higher resource utilization compared with those without influenza.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32636019     DOI: 10.1016/j.amjcard.2020.05.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.

Authors:  Orly Vardeny; KyungMann Kim; Jacob A Udell; Jacob Joseph; Akshay S Desai; Michael E Farkouh; Sheila M Hegde; Adrian F Hernandez; Allison McGeer; H Keipp Talbot; Inder Anand; Deepak L Bhatt; Christopher P Cannon; David DeMets; J Michael Gaziano; Shaun G Goodman; Kristin Nichol; Matthew C Tattersall; Jonathan L Temte; Janet Wittes; Clyde Yancy; Brian Claggett; Yi Chen; Lu Mao; Thomas C Havighurst; Lawton S Cooper; Scott D Solomon
Journal:  JAMA       Date:  2021-01-05       Impact factor: 157.335

2.  Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis.

Authors:  Bahar Behrouzi; Deepak L Bhatt; Christopher P Cannon; Orly Vardeny; Douglas S Lee; Scott D Solomon; Jacob A Udell
Journal:  JAMA Netw Open       Date:  2022-04-01

3.  Prevalence and prognostic implications of myocardial injury in patients with influenza.

Authors:  Anna M Nordenskjöld; Niklas Johansson; Erik Sunnefeldt; Simon Athlin; Ole Fröbert
Journal:  Eur Heart J Open       Date:  2022-08-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.